The acquisition would include $85 million at closing and up to an additional $165 million in growth-based earnout payments over the next four years, Conmed said in a news release.
The BioBrace implant is an FDA-cleared bioinductive scaffold designed to reinforce soft tissue where weakness exists and facilitate healing, according to Biorez.
The transaction is expected to close this month.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.